Atrial Fibrillation | Treatment Algorithms: Claims Data Analysis | US | 2023

Characterized by an abnormal heart rhythm that starts in the atrial chambers, atrial fibrillation (AF) is the most common arrhythmia in clinical practice. Management of AF targets the prevention and reoccurrence of the disease, risk assessment and prevention of stroke, ventricular rate control, and rhythm control. The choice of treatment is based on the cause and the time elapsed since the onset of symptoms. Pharmacological treatment includes rate control therapy (e.g., beta blockers, calcium channel blockers, digoxin) and anticoagulation therapy (e.g., vitamin K antagonists, novel oral anticoagulants [NOACs]). Surgical treatment is also an option for some patients. This claims data analysis shows treatment patterns and brand share by line of therapy for newly diagnosed and recently treated AF patients in United States.

Questions answered

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed AF patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed AF patients?
• How have NOACs (apixaban, rivaroxaban, edoxaban, and dabigatran) been integrated into the treatment algorithm, and what is their source of business?
• What percentage of AF patients receive drug therapy within two years of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?
• What percentage of AF patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States.

Key companies: Cardinal Health, Janssen Pharmaceuticals, Bristol Myers Squibb, Daiichi Sankyo, Almatica Pharma, Woodward Pharma, Baxter Healthcare, Validus Pharmaceuticals. 

Key drugs: Vitamin K antagonists; NOACs; class Ia, Ic, and III antiarrhythmics; beta blockers; calcium channel blockers; digitalis glycosides; antiplatelet agents.

Solution enhancement

The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.